Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004265
Status:
UNKNOWN
Last Update Posted:
2013-12-04
First Post:
2000-01-28
Brief Title:
Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer
Sponsor:
University of Wisconsin Madison
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Non-Small Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2000-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have recurrent or refractory non-small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have recurrent or refractory non-small cell lung cancer
Detailed Description:
OBJECTIVES I Determine the response rate and response duration in patients with recurrent or refractory non-small cell lung cancer NSCLC treated with second line paclitaxel II Determine the qualitative and quantitative toxicities of this treatment regimen in relapsed patients with recurrent NSCLC III Evaluate the time to treatment failure and overall survival in this patient population
OUTLINE Patients receive paclitaxel IV over 1 hour weekly for 6 weeks Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL Approximately 30-60 patients will be accrued for this study
OUTLINE Patients receive paclitaxel IV over 1 hour weekly for 6 weeks Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL Approximately 30-60 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1669 | None | None | None |
| WCCC-CO-98501 | None | None | None |